New Haven, CT

Dr. Sznol is currently Professor of Medicine and Leader, Melanoma/RCC Disease-Associated Research Team, at Yale University. He joined the Yale faculty in medical oncology in 2004 to lead melanoma and RCC clinical research programs and has taken several roles there including Chair of Protocol Review Committee, Chair of Quality Assurance and Compliance Committee, Associate Chief of Medical Oncology, and co-director of Yale Skin SPORE. His major interests include cancer immunotherapy, drug development for cancer, and treatment of patients with melanoma and renal cell carcinoma. 

Dr. Sznol graduated from Rice University in 1979 (BA, Biochemistry) and from Baylor College of Medicine, in Houston, Texas in 1982. He completed  internship and internal medicine residency programs at Baylor College of Medicine, Houston, Tx in 1985. He completed a fellowship in medical oncology at Mount Sinai College of Medicine in NYC in 1987. He joined the National Cancer Institute (NCI) as a Senior Investigator in the Investigational Drug Branch (IDB) of the Cancer Therapy Evaluation Program (CTEP). He was head of the Biologics Evaluation Program, IDB, CTEP, from 1994-1999, and responsible for clinical development of multiple biological and immune therapy agents. He attended in the Biological Response Modifiers Program, NCI, Fredrick, MD, 1988-1996, and the Immunotherapy Service of the Surgery Branch, NCI, in 1998 and 1999. In 1999, he left NCI to become Vice President of Clinical Development for Vion Pharmaceuticals in New Haven, CT.

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.